Shares of Iovance Biotherapeutics, Inc. (IOVA) surged 6.93% in a 24-hour period on Thursday, as investors responded positively to the company's impressive third-quarter 2025 financial results and business achievements. The biotechnology firm reported significant revenue growth and improved operational efficiency, sparking optimism in the market.

Iovance announced a 13% increase in total product revenue compared to the previous quarter, reaching approximately $68 million. This growth was primarily driven by U.S. Amtagvi sales of around $58 million and global Proleukin revenue of about $10 million. Notably, the company's gross margin improved to 43%, which management attributed to enhanced execution and operational efficiency.

The strong financial performance was complemented by positive developments in Iovance's business operations. The company reported growing demand for Amtagvi, its flagship product, and ongoing integration of community treatment centers. Additionally, Iovance highlighted continued progress in its development programs for solid tumor cancers, including positive interim data from the IOV-LUN-202 clinical trial for lifileucel in non-small cell lung cancer (NSCLC). The company also reaffirmed its full-year 2025 revenue guidance of $250 to $300 million, further boosting investor confidence in its growth trajectory.